Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse effects, questioning its efficacy.
The U.S. peptide therapeutics market had an estimated valuation of $21 billion in 2025, and is projected to grow to nearly $35 billion by 2035 (1). Injectable peptides are currently the most dominant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results